✦ LIBER ✦

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial

✍ Scribed by Moira Rynn; James Russell; Janelle Erickson; Michael J. Detke; Susan Ball; Jeff Dinkel; Karl Rickels; Joel Raskin

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 124 KB
Volume: 25
Category: Article
ISSN: 1091-4269
DOI: 10.1002/da.20271

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Escitalopram in the treatment of general

Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study

✍ Jonathan R.T. Davidson; Anjana Bose; Andrew Korotzer; Hongjie Zheng 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (1

Ritanserin in the treatment of generaliz

Ritanserin in the treatment of generalized anxiety disorders: A placebo-controlled trial

✍ E. A. Pangalila-Ratu Langi; A. A. I. Jansen 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

In a double-blind trial, 22 patients treated with 5 mg b.i.d. of the selective serotonin-S2 antagonist ritanserin for 4 weeks were compared with 26 patients treated with placebo for generalized anxiety disorder (DSM 111: 300.02). Symptoms were assessed using the Hamilton Anxiety Rating Scale (HARS)

Randomized placebo-controlled trial of e

Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder

✍ Anjana Bose; Andrew Korotzer; Carl Gommoll; Dayong Li 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

Efficacy and tolerability of duloxetine

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies

✍ Jonathan Davidson; Christer Allgulander; Mark H. Pollack; James Hartford; Janell 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Abstract ## Objective To assess the efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder (GAD). ## Methods Acute‐phase data from a subset of patients (≥65 years) with GAD were pooled from four randomized, double‐blind, placebo‐controlled trials of dulo

Safety and tolerability of duloxetine in

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

✍ James I. Hudson; Madelaine M. Wohlreich; Daniel K. Kajdasz; Craig H. Mallinckrod 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

## Abstract ## Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). ## Method Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were random

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety

✍ M. Linden; D. Hadler; S. Hofmann 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Generalized anxiety disorders are frequent, chronic, and disabling illnesses for which so far ideal drug treatment is not available. A new promising anxiolytic drug is DN-2327, a non-benzodiazepine isoindoline derivative, which has shown in animals to have anxiolytic, taming, antiaggressive, and ant